As first subcutaneous anti-CD38 mAb, Darzalex Faspro secures J&J’s lead in MM, shaves hours off infusion time

FDA’s approval of a subcutaneous form of Darzalex secures J&J’s leading position in the anti-CD38 market just two months after a new entrant threatened to cut into its market share. It’s also a game changer for multiple myeloma patients, cutting infusion time from hours to mere minutes.

Anti-CD38 mAbs have become one of the main pillars of MM treatment; however, the available IV formulations of the drugs take hours to infuse. The subcutaneous version of the anti-CD38 mAb Darzalex Faspro daratumumab and hyaluronidase-fihj, cuts the administration time to about three to five minutes, a change that’s especially beneficial during the COVID-19 pandemic. ...